ZYUS Life Sciences Inc. (“ZYUS”) announced today that it has completed the previously announced acquisition of Kentucky-based healthcare technology company Revon Systems, Inc. (“Revon”).
ZYUS, which is focused on the global development and commercialization of innovative and patient-focused cannabinoid-based therapeutics and product candidates, intends to utilize Revon’s proprietary artificial intelligence–enabled technology platform as a digital therapeutic patient interface and a real-time data collection platform during various future planned clinical studies and trials.
“We welcome the Revon team onboard at ZYUS and are excited to utilize the proprietary technology platform in future planned clinical trials of our pain treatment–related product candidates,” said Brent Zettl, President and CEO of ZYUS. “By generating a stronger interface and engagement with patients, we aim to help expedite the clinical trial process as we pursue innovative therapies to better the lives of patients.”
Date: August 13, 2019
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Business Wire
